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differentiation induced by retinoic acid or
overexpression of NDM29 non-coding RNA
Delfina Costa1,3, Arianna Gigoni1,3, Roberto Würth2, Ranieri Cancedda1,3, Tullio Florio2,4 and Aldo Pagano1,3*Abstract
Background: Metformin is a widely used oral hypoglycemizing agent recently proposed as potential anti-cancer
drug. In this study we report the antiproliferative effect of metformin treatment in a high risk neuroblastoma cell
model, focusing on possible effects associated to different levels of differentiation and/or tumor initiating potential.
Methods: Antiproliferative and cytotoxic effects of metformin were tested in human SKNBE2 and SH-SY5Y neuroblastoma
cell lines and in SKNBE2 cells in which differentiation is induced by retinoic acid treatment or stable overexpression of
NDM29 non-coding RNA, both conditions characterized by a neuron-like differentiated phenotype.
Results: We found that metformin significantly inhibits the proliferation of NB cells, an effect that correlates with the
inhibition of Akt, while AMPK activity resulted unchanged. Notably, metformin effects were modulated in a different ways
by differentiating stimuli, being abolished after retinoic acid treatment but potentiated by overexpression of NDM29.
Conclusion: These data suggest the efficacy of metformin as neuroblastoma anticancer agent, and support the
requirement of further studies on the possible role of the differentiation status on the antiproliferative effects of this drug.
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Metformin (N,N-dimethylbiguanide) is an oral biguanide
in clinical use since the 1950s for its hypoglycemic activity.
Currently, it is the most widely used anti-type 2 diabetes
drug, with nearly 120 million prescriptions worldwide filled
every year [1]. Metformin decreases hyperglycemia primar-
ily by activating 5’-adenosine monophosphate-activated
protein kinase (AMPK) to suppress glucose production in
the liver, increase glucose utilization, and reduce hyperin-
sulinemia [2].
Recent population studies suggested that metformin
decreases the incidence of several cancers and cancer-
mortality in diabetic patients [3-6], and improves the
response to chemotherapy in diabetic breast cancer* Correspondence: aldo.pagano@unige.it
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unless otherwise stated.patients [7]. Additionally, this therapeutic potential has
been confirmed in vitro since metformin inhibits in breast,
colon, lung, prostate, and pancreas cancer cell proliferation
[8-11]. These studies highlight a direct antitumoral activity
of metformin, besides the possible indirect effects medi-
ated by the improvement of the metabolic parameters
and, in particular, of the hyperinsulinemia. More recently,
prospective studies also demonstrated that preoperative
metformin treatment of non-diabetic patients with breast
(two weeks) or colorectal aberrant cryptic foci (one
month) provided a reduction of the number of prolifera-
tive cells [12,13].
Interestingly, it was shown that the antitumor effect
exerted by metformin in breast cancer, glioblastoma, and
hepatocellular carcinoma cells is mainly mediated by a
directed and selective antiproliferative activity against
the cancer stem/tumor initiating cell (TIC) fraction
[14-17]. According to the cancer stem cell theory this
cell subpopulation represents the main pharmacologicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mors [18-20].
In this work we address, for the first time, the possible
anticancer effect of metformin in a high risk neuroblast-
oma (NB) cell model, including cancer cell lines displaying
different levels of differentiation and stemness/tumor initi-
ating potential.
In particular, we document a significant inhibition of
NB cells proliferation and viability exerted by metformin.
Interestingly, overexpression of NDM29, a NB differenti-
ating non-coding (nc)-RNA, transcribed by RNA polymer-
ase III, and able to reduce cell tumorigenicity [21-23],
leads to an increased cell sensitivity towards metformin,
while all trans-retinoic acid (ATRA)-induced differenti-
ation reduced metformin NB cell susceptibility.
These findings provide the basis for further, deeper
investigations on the possible usefulness of metformin as
adjuvant/neo-adjuvant treatment for NB, and its specific
role in the stemness/differentiation balance of tumor cells.
Materials and methods
Cell Cultures and metformin treatment
Cell lines: SH-SY5Y, grown in DMEM (Sigma–Aldrich),
supplemented with 10% FBS (GIBCO), L-glutamine (2 mM;
EuroClone), and penicillin–streptomycin (100 U/ml/
100 μg/ml; EuroClone); SKNBE2, grown in RPMI (Sigma–
Aldrich), supplemented with 10% FBS (GIBCO), L-gluta
mine (2 mM; EuroClone), and penicillin–streptomycin (100
U/ml/ 100 μg/ml; Euro Clone).
SKNBE2 cells were transfected using polyethylenimine
(PEI; Sigma P3143) with pEGFP-N1 as control (hereafter
referred to as pMock) or pEGFP-N1-NDM29 (hereafter
referred to as NDM29). G418 (geneticin; Invitrogen) was
used in culture medium as mean of selection up to
1000 μg/ml, until resistant clones were identified. After se-
lection, the clones were preserved in 200 μg/ml G418 in
standard culture conditions. Treatment with metformin
(20 mM) was performed when cell culture reached 80% of
confluence. ATRA treatment was performed in SKNBE2
and SHSY5Y neuroblastoma cells grown in RPMI or
DMEM medium with 10% FBS. Cells were grown for
2 days to reach the log phase of growth. When cell cul-
tures reached 80% of confluence the medium was replaced
with RPMI or DMEM medium containing 10% FBS and
ATRA (1 or 10 μM) or DMSO (0.01% or 0.1%) in control
cultures. Cells were then grown for 10 days before the ex-
periments were performed.
Cell proliferation and cytotoxicity assays
A) Real time cell proliferation and cytotoxicity was
assessed by xCELLigence RTCA DP System (Roche,
Germany), as reported [24]. This system monitors cellular
events in real time by measuring electrical impedance
across interdigitated gold micro-electrodes integrated onthe bottom of tissue culture plates. The impedance meas-
urement provides quantitative information about the bio-
logical status of the cells, including cell number, viability,
and morphology. Cell-sensor impedance is expressed as
an arbitrary unit called Cell Index [25]. In order to calcu-
late CI, cells were seeded into 100 μL of standard medium
in 96X microtiter plates (E-Plate-Roche, Germany). Back-
ground impedance was determined using 50 μl of stand-
ard medium. After 24 hrs, 20 mM metformin was added
to the wells and cell proliferation was monitored for
72 hrs or more. Cell adhesion, spreading and proliferation
were monitored every 30 min using the xCELLigence sys-
tem to produce time-dependent cell response dynamic
curves. All experimental results were obtained using
RTCA Software 1.2 of the xCELLigence system.
B) Cell counting studies: cell from the different lines
were plated in 6-well plates, incubated in standard medium
for approximately 24 hrs before being treated with 20 mM
metformin. Cells were counted with a hemocytometer after
24 and 48 hrs of metformin treatment and evaluated by
Trypan blue exclusion test in which live cells are able to
exclude the dye from the cytosol.
C) [3H]-thymidine incorporation assay: different cell
lines were plated in 24-well plates, incubated in standard
medium for 24 hrs, then treated with 20 mM metformin.
After 24 and 48 hrs of metformin treatment, cells were
pulsed with [3H]-thymidine (0.3 μCi/500 μl/well) (GE
Healthcare, New York, NY) for the last 14 hrs. Averaged
proliferation rate was then calculated by the thymidine
uptake assay.
D) ATPlite 1step Luminescence assay: this system
measures cellular ATP levels, as a marker of cell viability
(Perkin Elmer, Monza, Italy). ATPlite 1step assay system
is based on the production of light caused by the reac-
tion of ATP with added luciferase and D-luciferin. The
emitted light is proportional to ATP concentration. Cell
suspension (100 μl) was seeded in 96-well culture plate
white (Thermo Scientific). After 24 hrs, 100 μl culture
medium containing metformin (20 mM) was added to the
cells. Each group had 5 repeats. The plates for the ATP-
Lite assay were incubated for 24 or 48 hrs at 37°C. Then
100 μl of culture medium was removed from each well
using a manual multichannel pipet, followed by the
addition to each well of 100 μl cell substrate solution
(ATPlite kit content). The plate was shaken for 2 min
followed by dark adapted for 10 min and luminescence
was measured using a luminometer (TECAN Genios Pro
reader).
E) SYTOX Blue dead cell stain: this is a high-affinity
nucleic acid stain that easily penetrates dead cells with
compromised plasma membranes but not in the healty
ones. Cells were plated in 6 well-plates, incubated in
standard medium for 24 hrs, and treated with 20 mM
metformin for 24 or 48 hrs at 37°C. After brief incubation
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esce bright blue when excited with 405 nm violet laser
light. Samples were analyzed using a Cyan ADP cytofluori-
meter (Beckman-Coulter, Brea CA, USA). For each sam-
ple, 20,000 events were acquired. The data were analyzed
using Summit 4.3.1 software (Beckman-Coulter, USA).
Western blotting
Cells were plated onto 60-mm dishes for 24 hrs before be-
ing treated. Cells were lysed in buffer containing 1% Noni-
det P-40, 20 mM Tris–HCl, pH 8, 137 mM NaCl, 10%
glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluor-
ide, 1 mM sodium orthovanadate, 10 mM NaF (all from
Sigma), and the “Complete” protease inhibitor mixture
(Roche Applied Science) for 10 min at 4°C [26]. Nuclei
were removed by centrifugation (13,200 rpm at 4°C, for
2 min), and total protein content was measured using the
Bradford assay (Bio-Rad). Proteins (20 μg) were resus-
pended in 2X reducing sample buffer (2% SDS, 62.5 mM
Tris, pH 6.8, 0.01% bromphenol blue, and 1.43 mM β-
mercaptoethanol, 0.1% glycerol), electrophoresed on 10%
SDS polyacrylamide gels, transferred on polyvinylidene
difluoride membrane (Bio-Rad), and probed with specific
antibodies directed against total and phospho-Akt (Ser-
473), total and phospho-AMPk, total and phospho-
mTOR, and procaspase-3 and cleaved caspase-3, all
purchased from Cell Signaling Technology (Beverly, MA);
α-tubulin (Sigma) was used as protein loading standard.
Immunocomplex detection was performed using ECL sys-
tem (Bio-Rad), as reported [27].
Real time quantitative RT-PCR analysis
Total RNAs from samples were extracted using TRIzol re-
agent (Invitrogen) according to the manufacturer’s protocol,
DNAseI-digested and subjected to reverse transcription by
Transcriptor High Fidelity cDNA Synthesis Kit (Roche
05081955001) following manufacturer’s instructions. The
total RNA from samples was measured by real-time quanti-
tative RT-PCR using PE ABI PRISM@ 7700 Sequence
Detection System (Perkin Elmer Corp./Applied Biosystems,
Foster City, CA) and SybrGreen method. The sequences of
forward and reverse primers were: NDM29, 5’-GGCAGG
CGGGTTCGTT-3’ and 5’-CCA CGCCTGGCTAAGTTT
TG-3’; neurofilament-68 (NF-68), 5’-CAAGGACGAGGT
GTCCG AG-3’ and 5’-CCCGGCATGCTTCGA; Integrin
beta-1 (CD29), 5’-AACGAGGTCATGGTT CATGTTG-3’
and 5’-ACCACACCAGCTACAATTGGAA-3’. For en-
dogenous control, the expression of glyceraldehyde 3 phos-
phate dehydrogenase (GAPDH) gene was examined. The
sequences for human GAPDH rRNA forward and reverse
primers were 5’-GAAGGTGAAG GTCGGAGTC-3’ and
5’-GAAGATGGTGATGGGATTTC-3’. Relative transcript
levels were determined from the relative standard curve
constructed from stock cDNA dilutions, and divided by thetarget quantity of the calibrator following manufacturer's
instructions.
Statistical analysis
Experiments were performed at least in triplicate. Data
are reported as mean values ± standard error (SE). Statis-
tical significance of observed differences among different
experimental groups was examined using the unpaired
Student's t-test, as reported [28]. Statistical analysis were
performed before normalization (metformin vs control).
Results
Metformin inhibits neuroblastoma cell growth
In order to investigate the effect of metformin on NB,
SKNBE2 cells were treated for 12–72 hrs with metformin
(20 mM) and proliferation rate analyzed using multiple
experimental approaches. First, we measured cell prolifer-
ation using the xCELLigence RTCA DP system. SKNBE2
growth curves showed a time-dependent decrease in the
proliferation rate of metformin-treated cells, resulting in a
statistically significant difference after 48 hrs (as evidenced
by the calculated Cell Index, see Methods), and lasting up
to the end of the experimental observation (72 hrs)
(Figure 1A).
In order to evaluate whether the reduction in Cell Index
was directly associated to a decrease of cell proliferation,
control and metformin-treated cells were counted using an
hemocytometer. Results confirmed a significant reduction
of the cell number 48 hrs after metformin administration
(Figure 1B). In addition, a statistically significant reduction
of the mitotic rate of metformin-treated SKNBE2 cells was
confirmed by a statistically significant decrease in DNA
synthesis 24 hrs after the treatment, measured by [3H]-thy-
midine incorporation (Figure 1C). Next, metformin effects
on cell viability were tested using the ATPlite assay, which,
measuring intracellular ATP content in metabolically active
cells, is an indirect index of cell viability. In agreement with
the previously described experiments, we found that, after
48 hrs of treatment, metformin leads to a statistically
significant decrease in ATP content (Figure 1D).
To strengthen these results, and verify whether metfor-
min effects were merely cytostatic or cytotoxicity was also
induced, we quantified, by FACS analysis, the percentage of
dead cells by SYTOX blue incorporation assay, in which
the intracellular accumulation of the dye is an index of dead
cells. Again, results showed that metformin increased the
number of cell death after 48 hrs of treatment (Figure 1E).
In order to assess the mechanism of cell death induced
by metformin we tested by Western blot the possible acti-
vation of the apoptotic machinery measuring the expres-
sion of the cleaved/activated caspase-3. However, 8, 24
and 48 hours of treatment with metformin 20 mM did not
increase the cleaved caspase-3 intracellular content and
unaltered caspase-3 pro-enzyme expression was detected
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Figure 1 Metformin reduces cell proliferation and viability of Neuroblastoma SKNBE2 cells. A) Cell Index curves reporting SKNBE2
neuroblastoma cell proliferation, untreated (CTR) or treated with metformin (Met), as resulting by Xelligence RTCA DP analysis. Histograms
highlight Cell Index values after 24 and 48 hrs. B) Cell counting assay of SKNBE2 cells untreated (CTR) or treated with metformin (Met). Y-axis is
referred to cell number x 106. C) [3H]-thymidine incorporation assay of SKNBE2 cells, untreated (CTR) or treated with metformin (Met). Y-axis is
referred to cpm x 103. D) Cell viability analysis of SKNBE2 cells untreated (CTR) or treated with metformin (Met) as determined by ATPlite assay.
Y-axis is referred to luminescence x 105. E) Cell death analysis by FACS analysis for sytox blue staining. The percentage of cell death is reported as
Met/CTR ratio. F) Western blot analysis of caspase-3 cleavage. Equal loading of proteins was ensured by normalization for pro-caspase 3 and α-
tubulin expression. Cleaved Caspase 3 was not detected. G) Western blot analysis of Akt phosphorylation/activation. 1 = Complete Medium (C.M.,
RPMI 10%), 2 = C.M. + 20 mM Met for 5 min, 3 = C.M. + 20 mM Met for 15 min, 4 = C.M. + 20 mM Met for 30 min, 5 = C.M. + 20 mM Met for
60 min. Equal loading of proteins was ensured by normalization for total Akt and α-tubulin expression. Densitometric analysis of phospho-Akt/
total Akt ratio is also reported. (*p < 0.05; **p < 0.01).
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ther the up-regulation of the pro-apoptotic protein Bax,
nor the presence of nuclear piknosis, both common fea-
tures of apoptotic cells (data not shown). Altogether theseresults exclude apoptosis from the major causes of cell
death induced by metformin.
To investigate at molecular level the intracellular
pathways altered by metformin to affect SKNBE2 cells
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phosphorylation/activation. Akt inhibition, known to cor-
relate with impaired cell survival, was recently shown to
represent a molecular correlate of metformin direct anti-
tumoral effects [15]. In Western blot experiments, we re-
port that metformin (20 mM) induced a long-lasting
(5–60 min) decline in Akt phosphorylation/activation
(Figure 1G), suggesting that metformin effects in SKNBE2
cells were mediated by the inhibition of Akt activity. Con-
versely, AMPK/mTOR pathways was not affected (see
below).
Since malignant potential of NB nodules is often
dependent on N-myc amplification/overexpression (as oc-
curs in SKNBE2 cells), we investigated whether the antitu-
moral effects of metformin are somehow modulated by
the activity of this oncogene. To this purpose we tested
metformin antiproliferative activity in the SH-SY5Y NB
cell line in which N-myc is not amplified [29]. Metformin
(20 mM) treatment induced a statistically significant re-
duction of proliferation rate after 48 hrs, also in SH-SY5Y
cells (Figure 2A). In addition, metformin effect on cell via-
bility was assessed by ATPlite assay, performed after 24
and 48 hrs of treatment. A reduction of cell viability was
detected although to a lesser extent respect to SKNBE2
cells, reaching statistical significance after 48 hrs of treat-
ment (Figure 2B). Interestingly, after 48 hrs of treatment,
SYTOX blue assay evidenced that metformin-induced cell
death in SH-SY5Y cells, although reaching statistical sig-
nificance, was less pronounced as compared to what ob-






































Figure 2 Metformin antiproliferative effects towards neuroblastoma c
in SH-SY5Y cells, untreated (CTR) or treated with metformin (Met). Y-axis is
untreated (CTR) or treated with metformin (Met), as determined by ATPlite as
by FACS analysis for SYTOX blue staining in untreated (CTR) or metformin (Me
(*p < 0.05; **p < 0.01).Altogether these results suggest that metformin is an
effective antiproliferative agent towards NB cell lines
with different malignant potential.
Effects of metformin on differentiated neuroblastoma
cell growth
NB is composed by extremely heterogeneous cell popula-
tions, including cells at different maturation stages. Thus,
we investigated the efficacy of metformin as antiprolifera-
tive agent in NB cells at different level of differentiation
and malignancy.
To this aim we first assessed the effects of the treatment
with metformin using SKNBE2 cells differentiated after
ATRA treatment (10 μM, for 10 days) that leads to a
neuron-like commitment (Figure 3A). Interestingly, in cell
count experiments, we found that the remarkable reduc-
tion of cell proliferation rate induced by metformin in
non-differentiated control cells, was greatly reduced in dif-
ferentiated SKNBE cells exposed to metformin, resulting
in a highly significant statistical difference comparing the
two experimental groups (Figure 3B). SYTOX blue assay
corroborated this evidence showing, after metformin
treatment, a significant increase of death rate in
non-differentiated cells, which was almost abolished in
SKNBE2 cells differentiated with ATRA (Figure 3C). In
order to discriminate between the antiproliferative effect
that ATRA exert per se and those induced by metformin
we treated SKNBE2 cells with a lower dose of ATRA
(1 μM, for 10 days). In this condition the treatment in-










































ell lines with different malignant potential. A) Cell counting assay
referred to cell number × 106. B) Cell viability analysis of SH-SY5Y cells
say. Y-axis is referred to luminescence × 105. C) Cell death quantification
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Figure 3 Retinoic acid-dependent differentiation of SKNBE2 cells decreases metformin antiproliferative effects. A) Morphological analysis
of SKNBE2 cell lines treated with retinoic acid (RA) 10 μM or vehicle (scale bar = 100 μm). B) Cell counting assay in SKNBE2 differentiated with
10 μM retinoic acid (RA) and the respective control, in the presence or absence of metformin (Met). The number of cells, are reported as Met/CTR
ratio. C) Cell death analysis by FACS analysis for SYTOX blue staining. The percentage of cell death is reported as Met/CTR ratio. D) Morphological
analysis of SKNBE2 cells treated with 1 μM retinoic acid (RA) or vehicle (scale bar = 200 μm). E) Cell counting assay of SKNBE2 cells treated with
1 μM retinoic acid (RA) and the respective control, in the presence or absence of metformin (Met). The number of cells, are reported as Met/CTR
ratio. F) Western blot analysis of AMPk and mTOR phosphorylation/activation induced by metformin (Met) before and after the induction of
RA-mediated differentiation of SKNBE2 cells. Equal loading of proteins was ensured by α-tubulin expression. G) Morphological analysis of SHSY5Y
cells treated with retinoic acid (RA) 1 μM or vehicle (scale bar = 100 μm). H) Cell counting assay in SHSY5Y cells, treated with retinoic acid (RA)
1 μM and the respective control, in the presence or absence of metformin (Met). The number of cells, are reported as Met/CTR ratio. Images were
taken by EVOS fl, AMG. (*p < 0.05; **p < 0.01; ***p < 0.001).
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cell counting experiments (Figure 3D,E). Therefore, ATRA
affects metformin susceptibility in SKNBE cells by inducing
NB cells differentiation in a dose-dependent manner.Since in differentiated hepatic cells metformin hypogly-
cemic effects are mainly mediated by the modulation of
the AMPK/mTOR pathway, we examined whether this
may occur also in differentiated NB cells. By western blot
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and mTOR phosphorylation before and after the induc-
tion of ATRA-mediated differentiation in SKNBE2 cells.
As reported in Figure 3F, no differences on the activity
(phosphorylation) of AMPk or mTOR has been found in
both differentiated and undifferentiated cells. Altogether,
these results show that the susceptibility to the effects of
metformin is directly correlated to NB differentiation
level, as reported in glioblastoma cells [15] and confirmed
that AMPK seems not involved in the antiproliferative ef-
fects of the drug.
Next we investigated the occurrence of this effect in NB
cells highly responsive to ATRA-induced differentiation.
We found that, although less sensitive to metformin than
SKNBE2 cells, SHSY5Y cells were highly influenced by
ATRA treatment (1 μM, for 10 days) that completely abol-
ished the ability of metformin to reduce cell proliferation
(Figure 3G,H). Higher ATRA concentrations (10 μM, for
10 days) did not lead to additional changes in metformin
susceptibility (data not shown).SKNBE2-Mock SKNBA B




































Figure 4 NDM29 expression level correlates with the differentiation o
expressing the basal level of NDM29 ncRNA; B,C) SKNBE2-S2 and SKNBE2-S
Upper panels: transmitted light microscopy (EVOS fl, AMG). Lower panels: f
Jena Germany). Blue = DAPI, green = GFP (scale bar = 25 μm). D) Real time
(adhesion marker) expression.To delve deeper into the mechanisms by which differen-
tiation may affect metformin antiproliferative effects in
NB cells, we took advantage of a novel in vitro model of
NB differentiation, we recently developed, that was based
on the expression level of a nc-RNA, named NDM29, in
SKNBE2 cells [21,22,30]. In this system the level of differ-
entiation of NB cells, as well as the reduction of the stem-
ness/tumor initiating potential, is directly related to the
level of synthesis of NDM29 [21,22,30]. Here, we com-
pared the effects of metformin in mock transfected cells,
that express low levels of endogenous NDM29 RNA, with
established cell lines in which different levels of NDM29
are overexpressed. The overexpression of ncRNA NDM29
represent a novel model of NB cell differentiation, result-
ing in the acquisition of neuronal electrophysiological
properties as previously reported [22].
In particular, we used the following permanently trans-
fected cell lines: SKNBE2 cells that express NDM29 at en-
dogenous level (transfected with the empty vector,
pMock), NDM29 overexpressing cells, showing increasedE2-S2 SKNBE2-S1C

























f NB cells toward a neuron-like phenotype. A) SKNBE2-Mock cells
1 cells expressing increased level of NDM29 [21]; (scale bar = 50 μm).
luorescence microscopy (Zeiss Axiovert 200 M inverted microscope,
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Figure 5 (See legend on next page.)
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Figure 5 Higher efficacy of metformin antiproliferative effects in NDM29 differentiated neuroblastoma cell populations. A) Cell Index
curves of the SKNBE2-S2 and SKNBE-S1 NB cell proliferation untreated (CTR) or treated with metformin (Met), as resulting by Xcelligence RTCA DP
analysis. B) Cell Index analysis of SKNBE2-Mock, SKNBE2-S2 and SKNBE2-S1 NB cells untreated (CTR) or treated with metformin (Met), as resulting
by Xcelligence RTCA DP analysis. Data were reported as Met/CTR ratio for each cell line. Histogram on the right panel report statistical analysis of
24 and 48 hrs cell index measures. C) Cell counting assay and D) [3H]-thymidine incorporation assay of SKNBE2-Mock, SKNBE2-S2 and SKNBE2-S1
cells untreated (CTR) or treated with metformin (Met). Cell number (C) and cpm (D) values are reported as Met/CTR ratio for each cell type. E)
FACS analysis of cell dead with SYTOX blue stain of different cell lines (SKNBE2-Mock, S2, S1). The percentage of cell death is reported as Met/CTR
ratio, for each cell type. F) Cell viability determination by ATPlite assay in different cell lines (SKNBE2-Mock, S2 and S1) untreated (CTR) or treated
with metformin (Met). Luminescence values, are reported as Met/CTR ratio for each cell type. G) Morphology of S1 cells (scale bar = 200 μm) by
EVOS fl, AMG. (*p < 0.05; **p < 0.01; ***p < 0.001).
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pMock cells. As depicted in Figure 4, NDM29 stably
transfected cells, co-expressing GFP, show a strong enrich-
ment in neuritic processes, acquiring a frank neuronal
morphology, associated to the expression of neuronal
(neurofilament NF-68) and adhesion (CD29) markers. Im-
portantly, the acquisition of all the differentiation features
were proportional to the expression level of NDM29
(Figure 4A-D). Cells from all these lines were treated for
48 hrs with metformin (20 mM) and tested for cell prolif-
eration rate. Surprisingly, by Xcelligence detection system,
we observed that metformin was able to affect cell prolif-
eration also in the differentiated S2 and S1 cell lines
(Figure 5A). Interestingly, we found that metformin activ-
ity was directly correlated to NDM29 expression, which,
in turn, determines the differentiation level of the cells. In-
deed, higher metformin-dependent inhibition of cell pro-
liferation was observed in well-differentiated S1 cells than
in mock-transfected cells (Figure 5B). In order to better
associate these effects to cell proliferation rather than an
artifactual parameter detected by this system, such as cell
area, these data were confirmed in cell counting and [3H]-
thymidine incorporation experiments showing that
metformin inhibition of DNA synthesis showed a higher
statistical significance in NDM29-overexpressing cells as
compared to mock cells (Figure 5C,D). In agreement with
these results, FACS analysis for SYTOX blue staining,
after 24 hours of metformin treatment, showed increased
SKNBE2 death rate directly correlated with NDM29 ex-
pression (Figure 5E), and ATPlite assay showed decreased
cell viability, proportional to the levels of NDM29 expres-
sion (Figure 5F). Interestingly, microscopic examination
revealed a dramatic alteration in the morphology of
metformin-treated S1 cells that acquired large, elongated
shape recapitulating a behavior previously observed in gli-
oma cell lines (Figure 5G) [31,32].
These results highlight an unexpected different modula-
tion of the response to metformin after NB cell differenti-
ation, which is not correlated to differentiation per se but
directly depend on the expression level of NDM29 ncRNA.
We previously reported that NDM29 sensitizes SKNBE2
cells to several cytotoxic drugs (cisplatin, doxorubicin) by
powerfully down-regulating MDR1 expression [21]. Thus,we verified whether the increased sensitivity of metformin
observed in S1 cells might be related to NDM29-
dependent alterations of the expression of molecules
involved in the metformin interaction with the cells. In
particular, we focused on the expression of the organic
cation transporter 1 (OCT-1) that represents one of the
main regulators of metformin cell internalization. How-
ever, in Western blot analysis we did not find significant
differences in OCT-1 expression in pMock, S1 and S2
cells (data not shown), suggesting that different mecha-
nisms should be responsible of the higher sensitivity to
metformin of NDM29 expressing cells. Conversely, we
observed that in SH-SY5Y OCT-1 expression was slightly
reduced after metformin treatment (data not shown), pos-
sibly representing the molecular correlate for the lower
sensitivity of these cells as compared to SKBNE2.
Discussion
Besides being a first-line antidiabetic drug, metformin is
currently under consideration for additional anticancer
properties [33-35]. Recent reports evidenced TICs from
different cancer types as the preferential targets of this
drug [14-16]. These studies are in line with reports show-
ing that also other antidiabetic drugs, such as PPAR-γ ago-
nists exert cytostatic effects [36,37].
In this study we report, for the first time, an antiprolifer-
ative effect of metformin in a high-risk NB cell model. We
show that metformin induces a significant reduction in
the proliferation rate in two different NB cell lines
(SKNBE2 and SH-SY5Y) characterized by different N-myc
expression, although a higher sensitivity was observed in
the first one. While we cannot provide a definitive answer
for this difference, the observation that in SH-SY5Y cells,
OCT-1 expression, which control the cellular internaliza-
tion of this metformin, is down-regulated upon metformin
treatment, could account for this difference.
In line with previous studies [15], this effect was related
to a powerful inhibition of Akt activation, suggesting that
the treatment with metformin could directly act on cell
viability. In fact, beside an effect on cell cycle progression,
as suggested by the reduction of DNA synthesis in [3H]-
thymidine incorporation experiments, also increased cell
death was observed in SYTOX blue staining experiments.
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were the results of activation of apoptosis since we did not
detect nuclear shrinkage, caspase 3 activation or Bax up-
regulation. Thus, from our data metformin elicits mainly a
cytostatic effect that could indirectly cause cell death via
apoptosis-independent pathways.
Interestingly, no changes in AMPK activity was ob-
served in NB cells, although this kinase was reported to
represent a key intracellular mechanism in metformin
effects [38]. However, several studies suggested that mech-
anisms, others than AMPK activation, could mediate anti-
proliferative activity of metformin [39-41]. In particular,
although several different mechanisms were identified in
different tumoral cells, down-regulation of IGF-1 or other
growth factor mediated autocrine signalling was suggested
as main antiproliferative mechanisms regulated by metfor-
min [42,43]. In turn, this effect could be responsible for
the inhibition of pro-survival intracellular pathways, such
as Akt, as we show in this study in NB cells and previously
reported in GBM TICs [15]. However, further studies are
still required to definitely address this issue.
Importantly, as shown in several other tumor cell
types [14,15], metformin antitumoral activity was signifi-
cantly higher in less differentiated NB cells, with a lower
effect in differentiated cells (here we used ATRA-
dependent differentiation).
Conversely, we found that metformin sensitivity is
highly increased in NB cells in which differentiation is in-
duced by NDM29 overexpression. This effect was strictly
dependent on the expression levels of this ncRNA, which
also correlate with the induction of NB cell differentiation.
These data, and in particular the direct relationship be-
tween NDM29 expression and the reduction of NB cell
viability induced by metformin, strongly suggest the possi-
bility of a causal effect between the two events. At present
we do not know the exact molecular mechanisms by
which NDM29-dependent differentiation increases NB
cell susceptibility to metformin, at odd with ATRA effects.
In particular, since we previously reported that NDM29
overexpression inhibits MDR1 expression, representing a
molecular mechanism that increases NB cell vulnerability
to antimitotic cytotoxic drugs [21], we hypothesized that
NDM29 expression might affect susceptibility to metfor-
min inducing OCT-1 expression, thus increasing the
amount of drug internalized into the cells and able to
interfere with survival signals, such as Akt activity. How-
ever, here we report that SKBNE2 cells express similar
OCT-1 content independently from the levels of NDM29
expression, and thus a different molecular mechanism
needs to be identified.
Conclusions
Our study for the first time demonstrates that metfor-
min exerts antitumor activity against high risk NB cells,reducing cell proliferation and viability, via inhibition of
Akt phosphorylation, showing higher sensitivity for less
differentiated, highly proliferative cells. These data repre-
sent the starting point for further studies aimed to test
the possible application of metformin in NB therapy.
Moreover, as already shown for other cytotoxic drugs,
the overexpression of NDM29, although inducing neur-
onal differentiation, powerfully sensitizes NB cells to
metformin antiproliferative effects, suggesting that the
pharmacological modulation of the expression of this
ncRNA may represent a potential goal in the NB ther-
apy. The molecular determinants by which the differen-
tiation induced by NDM29, but not by retinoic acid,
increases the antiproliferative activity of metformin will
also represent a future goal in the translational research
of novel NB therapies.
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